参考文献
［1］Escudier B,Porta C,Schmidinger M,et al.Renal cell carcinoma:ESMO clinical practice guidelines for diagnosis,treatment and follow-updagger[J].Ann Oncol,2019,30（5）:706-720.
［2］Cobucci RN,Lima PH,de Souza PC,et al.Assessing the impact of HAART on the incidence of defining and non-defining AIDScancers among patients with HIV/AIDS:A systematic review[J].J Infect Public Health,2015,8（1）:1-10.
［3］Moch H,Cubilla AL,Humphrey PA,et al.The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A:Renal,penile,and testicular tumours[J].Eur Urol,2016,70（1）:93-105.
［4］Trpkov K,Hes O,Williamson SR,et al.New developments in existing WHO entities and evolving molecular concepts:The genitourinary pathology society（GUPS）update on renal neoplasia[J].Mod Pathol,2021,34（7）:1392-1424.
［5］Al-Bayati O,Hasan A,Pruthi D,et al.Systematic review of modifiable risk factors for kidney cancer[J].Urol Oncol,2019,37（6）:359-371.
［6］Kroeger N,Li H,De Velasco G,et al.Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies[J].Clin Genitourin Cancer,2019,17（1）:65-71.
［7］Minami T,Inoue M,Sawada N,et al.Alcohol consumption,tobacco smoking,and subsequent risk of renal cell carcinoma:The JPHC study[J].Cancer Sci,2021,112（12）:5068-5077.
［8］Regan S,Meigs JB,Grinspoon SK,et al.Determinants of smoking and quitting in HIV-infected individuals[J].PloS One,2016,11（4）:e0153103.
［9］Renehan AG,Tyson M,Egger M,et al.Body-mass index and incidence of cancer:A systematic review and meta-analysis of prospective observational studies[J].Lancet,2008,371（9612）:569-578.
［10］Choi Y,Park B,Jeong BC,et al.Body mass index and survival in patients with renal cell carcinoma:A clinical-based cohort and meta-analysis[J].Int JCancer,2013,132（3）:625-634.
［11］Plonski JJS,Fernandez-Pello S,Jimenez LR,et al.Impact of body mass index on survival of metastatic renal cancer[J].J Kidney Cancer VHL,2021,8（2）:49-54.
［12］Hidayat K,Du X,Zou SY,et al.Blood pressure and kidney cancer risk:Metaanalysis of prospective studies[J].J Hypertens,2017,35（7）:1333-1344.
［13］Ong WL,King K,Koh TL,et al.HIV and renal cell carcinoma:Experience in an australian statewide HIV center[J].Asia Pac J Clin Oncol,2016,12（2）:188-193.［14］Zhang M,Zhu Z,Xue W,et al.Human immunodefificiency virus related renal cell carcinoma:A retrospective study of 19 cases[J].Infect Agent Cancer,2021,16（1）:26.
［15］Bui TO,Dao VT,Nguyen VT,et al.Genomics of clear-cell renal cell carcinoma:A systematic review and meta-analysis[J].Eur Urol,2022,81（4）:349-361.(https://www.daowen.com)
［16］Mousnier A,Kubat N,Massias-Simon A,et al.Von Hippel-Lindau binding protein 1-mediated degradation of integrase affects HIV-1 gene expression at a postintegration step[J].Proc Natl Acad Sci USA,2007,104（34）:13615-13620.
［17］Sankineni S,Brown A,Cieciera M,et al.Imaging of renal cell carcinoma[J].Urol Oncol,2016,34（3）:147-155.
［18］Haliloglu AH,Gulpinar O,Ozden E,et al.Urinary ultrasonography in screening incidental renal cell carcinoma:Is it obligatory?[J].Int Urol Nephrol,2011,43（3）:687-690.
［19］Adams LC,Ralla B,Bender YY,et al.Renal cell carcinoma with venous extension:Prediction of inferior vena cava wall invasion by MRI[J].Cancer Imaging,2018,18（1）:17.
［20］Ljungberg B,Albiges L,Abu-Ghanem Y,et al.European association of urology guidelines on renal cell carcinoma:The 2019 update[J].Eur Urol,2019,75（5）:799-810.
［21］Chowdhury N,Drake CG.Kidney Cancer:An overview of current therapeutic Approaches[J].Urol Clin North Am,2020,47（4）:419-431.
［22］Powles T.Recent update to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer:Renal Cell Carcinoma:ESMO Clinical Practice Guidelines for Diagnosis,Treatment and Follow-Up[J].Ann Oncol,2021,32（3）:422-423.
［23］Blackburn SD,Shin H,Haining WN,et al.Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection[J].Nat Immunol,2009,10（1）:29-37.
［24］El-Far M,Halwani R,Said E,et al.T-cell exhaustion in HIV infection[J].Curr HIV/AIDS Rep,2008,5（1）:13-19.
［25］Uldrick TS,Adams SV,Fromentin R,et al.Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy[J].Sci Transl Med,2022,14（629）:eabl3836.
［26］Landriscina M,Altamura SA,Roca L,et al.Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma[J].Int J Cancer,2008,122（12）:2842-2850.
［27］Reuss JE,Stern D,Foster JC,et al.Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in Anti-PD1/PDL1 clinical trials[J].JAMA Netw Open,2020,3（12）:e2027110.
［28］Coghill AE,Pfeiffer RM,Shiels MS,et al.Excess mortality among HIV infected individuals with cancer in the United States[J].Cancer Epidemiol Biomark Prev,2017,26（7）:1027-1033.
［29］Vora KB,Ricciuti B,Awad MM.Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials[J].Sci Rep,2021,11（1）:1-6.